| Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval M Tolar, S Abushakra, JA Hey, A Porsteinsson, M Sabbagh Alzheimer's research & therapy 12 (1), 95, 2020 | 330 | 2020 |
| The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis M Tolar, S Abushakra, M Sabbagh Alzheimer's & Dementia 16 (11), 1553-1560, 2020 | 228 | 2020 |
| Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity M Tolar, JN Keller, S Chan, MP Mattson, MA Marques, KA Crutcher Journal of Neuroscience 19 (16), 7100-7110, 1999 | 194 | 1999 |
| Spatial navigation testing discriminates two types of amnestic mild cognitive impairment J Laczó, K Vlček, M Vyhnálek, O Vajnerová, M Ort, I Holmerová, M Tolar, ... Behavioural brain research 202 (2), 252-259, 2009 | 172 | 2009 |
| Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated M Tolar, MA Marques, JAK Harmony, KA Crutcher Journal of Neuroscience 17 (15), 5678-5686, 1997 | 136 | 1997 |
| Human analogue of the morris water maze for testing subjects at risk of Alzheimer’s disease J Laczó, R Andel, M Vyhnalek, K Vlcek, H Magerova, A Varjassyova, ... Neurodegenerative Diseases 7 (1-3), 148-152, 2010 | 114 | 2010 |
| Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression M Tolar, J Hey, A Power, S Abushakra International journal of molecular sciences 22 (12), 6355, 2021 | 112 | 2021 |
| A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity MA Marques, M Tolar, JAK Harmony, KA Crutcher Neuroreport 7 (15), 2529-2532, 1996 | 112 | 1996 |
| Imaging is superior to cognitive testing for early diagnosis of Alzheimer’s disease E Zamrini, S De Santi, M Tolar Neurobiology of aging 25 (5), 685-691, 2004 | 108 | 2004 |
| Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease JA Hey, JY Yu, M Versavel, S Abushakra, P Kocis, A Power, PL Kaplan, ... Clinical pharmacokinetics 57, 315-333, 2018 | 100 | 2018 |
| Spatial navigation and APOE in amnestic mild cognitive impairment J Laczó, R Andel, K Vlček, V Macoška, M Vyhnálek, M Tolar, M Bojar, ... Neurodegenerative diseases 8 (4), 169-177, 2011 | 94 | 2011 |
| Elucidating the Aβ42 anti-aggregation mechanism of action of tramiprosate in Alzheimer’s disease: integrating molecular analytical methods, pharmacokinetic and clinical data P Kocis, M Tolar, J Yu, W Sinko, S Ray, K Blennow, H Fillit, JA Hey CNS drugs 31, 495-509, 2017 | 85 | 2017 |
| Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potential S Abushakra, A Porsteinsson, P Scheltens, C Sadowsky, B Vellas, ... J Prev Alzheimers Dis 4 (3), 149-156, 2017 | 71 | 2017 |
| Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the “APOE4 Gene-Dose Effect” S Abushakra, A Porsteinsson, B Vellas, J Cummings, S Gauthier, JA Hey, ... J Prev Alzheimers Dis 3 (4), 219-228, 2016 | 68 | 2016 |
| Neurite degeneration elicited by apolipoprotein E peptides KA Crutcher, MA Clay, SA Scott, X Tian, M Tolar, JAK Harmony Experimental neurology 130 (1), 120-126, 1994 | 62 | 1994 |
| Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain JA Hey, P Kocis, J Hort, S Abushakra, A Power, M Vyhnálek, JY Yu, ... CNS drugs 32, 849-861, 2018 | 52 | 2018 |
| Apolipoprotein E exhibits isoform-specific neurotoxicity MA Marques, M Tolar, KA Crutcher Alzheimer's Research 3 (1), 1-6, 1997 | 28 | 1997 |
| APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline S Abushakra, AP Porsteinsson, M Sabbagh, L Bracoud, J Schaerer, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 6 (1 …, 2020 | 17 | 2020 |
| Sympathetic neurite outgrowth is greater on plaque-poor vs. plaque-rich regions of Alzheimer's disease cryostat sections M Tolar, SA Scott, KA Crutcher Brain research 787 (1), 49-58, 1998 | 9 | 1998 |
| Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous AD patients: efficacy and safety analyses from two Phase 3 trials S Abushakra, B Vellas, J Cummings, J Hey, M Tolar, A Power Neurobiology of Aging 1 (39), S22, 2016 | 6 | 2016 |
